UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review

Clinical and Applied Thrombosis/Hemostasis, 2018-05, Vol.24 (4), p.549-559

2018

Link zum Volltext

Verfügbarkeit prüfen

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Child abuse & neglect, 2003-11, Vol.27 (11), p.1247-1258

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety update on the use of recombinant activated factor VII in approved indications

Blood reviews, 2015-06, Vol.29, p.S34-S41

2015

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

BMJ open diabetes research & care, 2023-06, Vol.11 (3), p.e003300

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Blood, 2020-11, Vol.136 (Supplement 1), p.40-40

2020

Link zum Volltext

Verfügbarkeit prüfen

Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial

Thrombosis and haemostasis, 2007-10, Vol.98 (4), p.726

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

Transfusion (Philadelphia, Pa.), 2002-02, Vol.42 (2), p.190-197

2002

Link zum Volltext

Verfügbarkeit prüfen

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 Suppl 5, p.1-2

Seremetis, Stephanie

2012

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s5), p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

Introduction

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18, p.1-2

SEREMETIS, STEPHANIE

2012

Link zum Volltext

Verfügbarkeit prüfen

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Blood, 2022-11, Vol.140 (Supplement 1), p.5630-5631

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion

Thrombosis and haemostasis, 2003-05, Vol.89 (5), p.803

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Journal of thrombosis and haemostasis, 2019-09, Vol.17 (9), p.1470-1477

2019

Link zum Volltext

Verfügbarkeit prüfen

The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia

Thrombosis and haemostasis, 2002-10, Vol.88 (4), p.545

2002

Link zum Volltext

Verfügbarkeit prüfen

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

Blood, 2017-12, Vol.130, p.2372-2372

2017

Link zum Volltext

Verfügbarkeit prüfen

The use of recombinant activated factor VII in patients with acquired haemophilia

Blood reviews, 2015-06, Vol.29, p.S19-S25

2015

Link zum Volltext

Verfügbarkeit prüfen

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Blood coagulation & fibrinolysis, 2003-06, Vol.14 Suppl 1 (SUPPLEMENT 1), p.S29-S30

Seremetis, Stephanie

2003

Link zum Volltext

Verfügbarkeit prüfen

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Clinical investigation, 2015-09, Vol.5 (9), p.755-766

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-09, Vol.15 (5), p.1074-1082

2009

Link zum Volltext

Verfügbarkeit prüfen

Turoctocog alfa and drug development for hemophilia A

Expert opinion on orphan drugs, 2014-04, Vol.2 (4), p.419-431

2014

Link zum Volltext

Verfügbarkeit prüfen

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Blood coagulation & fibrinolysis, 2009-10, Vol.20 (7), p.488-493

2009

Link zum Volltext

Verfügbarkeit prüfen

Recombinant activated Factor VII in major surgery and trauma patients: a response

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Link zum Volltext

Verfügbarkeit prüfen

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Expert opinion on drug safety, 2005-09, Vol.4 (5), p.813-814

2005

Link zum Volltext

Verfügbarkeit prüfen

Evidence-based use of recombinant FVIIa (NovoSeven® , NiaStase® ) for the treatment of hemophilia with inhibitors in children and adolescents

Transfusion and apheresis science, 2008-02, Vol.38 (1), p.25-32

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(34)
Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Biological And Medical Sciences
(20)
Hematology
(18)
Medical Sciences
(16)
Adult
(11)
Hematologic And Hematopoietic Diseases
(11)
Female
(9)
Adolescent
(8)
Male
(7)
Middle Aged
(7)
Aged
(6)
Child
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Hemophilia
(6)
Hemophilia A - Drug Therapy
(6)
Inhibitors
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Cardiovascular System & Cardiology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Safety update on the use of recombinant activated factor VII in approved indications

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

11th Novo Nordisk Symposium on Haemostasis Management Vienna, Austria. 19-21 October 2011. Introduction

Introduction

Introduction

Introduction

Mim8 Clinical Development Program: An Overview of the Frontier Studies

Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia

Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis

The use of recombinant activated factor VII in patients with acquired haemophilia

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

Turoctocog alfa and drug development for hemophilia A

Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review

Recombinant activated Factor VII in major surgery and trauma patients: a response

Recombinant activated Factor VII in major surgery and trauma patients: a response: Wilson SJ, Bellamy MC, Giannoudis PV: The safety and efficacy of the administration of recombinant activated Factor VII in major surgery and trauma patients. Expert Opin. Drug Saf. (2005) 4(3):557-570

Evidence-based use of recombinant FVIIa (NovoSeven® , NiaStase® ) for the treatment of hemophilia with inhibitors in children and adolescents

Suchergebnisse filtern